Astrazeneca PLC ($AZN) Stock Forecast: Down 0.7% Today

What is Astrazeneca PLC?

AstraZeneca (AZN) is a pharmaceutical company known for its innovative treatments in various medical fields. The stock market had a bearish movement today.

Why is Astrazeneca PLC going down?

AZN stock is down 0.7% on Apr 16, 2024 17:46

• Promising data from the TOPAZ-1 Phase 3 trial of Imfinzi in combination with chemotherapy for biliary tract cancer was released, showing positive long-term overall survival results.
• Despite the positive news, the market may have reacted bearishly due to broader market conditions or profit-taking after recent gains.
• The volume spike in Aster DM Healthcare Ltd and other stocks could indicate shifting investor interest away from pharmaceuticals temporarily, impacting AZN's stock negatively.
• A warning shot fired by L%26G at AstraZeneca over executive pay could have also contributed to the bearish sentiment surrounding the stock.

AZN Price Chart

AZN News

AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows - AstraZeneca ( NASDAQ:AZN )

AstraZeneca Plc AZN released updated exploratory results from the TOPAZ-1 Phase 3 trial of Imfinzi ( durvalumab ) in combination with standard-of-care chemotherapy for advanced biliary tract cancer ( BTC ) .

https://www.benzinga.com/general/biotech/24/04/38269196/astrazenecas-imfinzichemo-combo-doubles-overall-survival-in-biliary-tract-cancer-patients-at-3-ye

AstraZeneca''s IMFINZI Plus Chemotherapy Reduces Death Risk By 26% At 3 Yrs. In TOPAZ-1 Phase 3 Study

LONDON (dpa-AFX) - AstraZeneca PLC (AZN.L) Tuesday announced follow-up data for TOPAZ-1 Phase III trial showing IMFINZI plus chemotherapy demonstrated clinically meaningful long-term overall survi…

https://www.finanznachrichten.de/nachrichten-2024-04/61959342-astrazeneca-s-imfinzi-plus-chemotherapy-reduces-death-risk-by-26-at-3-yrs-in-topaz-1-phase-3-study-020.htm

3 Pharma Stocks That Are Money-Printing Machines in 2024

The future of the U.S. economy appears promising, with robust growth and strong corporate performance. This economic strength has propelled the stock market to record highs, signaling confidence in the economy’s resilience. The well established pharmaceutical industry continues to assert its economic dominance through resolute financials. In 2022, pharma stocks brought in $510.5 billion, with forecasts for the sector to reach $863.6 billion in revenue by 2030. Between 2023 and 2030, the industry is expected to hold a solid CAGR of 7.8%. Investing in pharma stocks is very beneficial, especially for these top three companies.

https://investorplace.com/2024/04/3-pharma-stocks-that-are-money-printing-machines-in-2024/

Volumes spurt at Aster DM Healthcare Ltd counter

Aster DM Healthcare Ltd registered volume of 8.02 lakh shares by 10:46 IST on BSE, a 6.78 fold spurt over two-week average daily volume of 1.18 lakh shares Ramkrishna Forgings Ltd, Bayer CropScience Ltd, Tata Power Company Ltd, Astrazeneca Pharma India Ltd are among the other stocks to see a ...

https://www.business-standard.com/markets/capital-market-news/volumes-spurt-at-aster-dm-healthcare-ltd-counter-124041500188_1.html

Sunday papers: Trouble at Tesla? The headache facing Elon Musk

And L%26G fires warning shot at AstraZeneca over Pascal Soriot pay.

https://citywire.com/funds-insider/news/sunday-papers-trouble-at-tesla-the-headache-facing-elon-musk/a2440290

Trending Today

Injective ($INJ) Crypto Forecast: Down 8.4% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Down 5.5% Today

Robinhood Inc. ($HOOD) Stock Forecast: Up 11.0% Today

Sui ($SUI) Crypto Forecast: Down 5.8% Today

Alibaba Group Holding Limited ($BABA) Stock Forecast: Down 7.3% Today

Palo Alto Networks Inc. ($PANW) Stock Forecast: Up 5.1% Today

dogwifhat ($WIF) Crypto Forecast: Down 9.3% Today

Fetch.ai ($FET) Crypto Forecast: Down 5.3% Today

NEAR Protocol ($NEAR) Crypto Forecast: Down 6.1% Today

Aptos ($APT) Crypto Forecast: Up 5.8% Today

Astrazeneca PLC Price History

16.03.2024 - AZN Stock was down 0.7%

• Promising data from the TOPAZ-1 Phase 3 trial of Imfinzi in combination with chemotherapy for biliary tract cancer was released, showing positive long-term overall survival results.
• Despite the positive news, the market may have reacted bearishly due to broader market conditions or profit-taking after recent gains.
• The volume spike in Aster DM Healthcare Ltd and other stocks could indicate shifting investor interest away from pharmaceuticals temporarily, impacting AZN's stock negatively.
• A warning shot fired by L%26G at AstraZeneca over executive pay could have also contributed to the bearish sentiment surrounding the stock.